Efficacy of supervised toothbrushing program among school children in Kavrepalanchowk district of Nepal: A cluster randomized controlled trial. - Efficacy of supervised toothbrushing program among school children in Kavrepalanchowk district of Nepal: A cluster randomized controlled trial

Start Date10 Jan 2024

Sponsor / Collaborator

Tokyo Women's Medical University

JPRN-UMIN000049240

/ SuspendedNot ApplicableIIT

Biomarker for malignant pleural mesothelioma - Biomarker for malignant pleural mesothelioma

Start Date19 Aug 2022

Sponsor / Collaborator

Tokyo Women's Medical University

JPRN-UMIN000034400

/ CompletedNot ApplicableIIT

Effects of using infant pillows continuously for affecting motor development in preterm infants - Effects of using infant pillows for affecting motor development in preterm infants

Start Date01 Nov 2018

Sponsor / Collaborator

Tokyo Women's Medical University

[+1]

100 Clinical Results associated with Tokyo Women's Medical University

0 Patents (Medical) associated with Tokyo Women's Medical University

16,117

Literatures (Medical) associated with Tokyo Women's Medical University

31 Dec 2025·Science and Technology of Advanced Materials

Molecular design of dynamically thermoresponsive biomaterials

Review

Author: Nakayama, Masamichi ; Kobayashi, Jun ; Nagase, Kenichi

Dynamically thermoresponsive biomaterials, particularly those utilizing poly(N-isopropylacrylamide) (PNIPAAm), have attracted much attention in biomedical applications due to their reversible phase transition near body temperature. These biomaterials provide innovations across drug delivery system, chromatography, and tissue engineering. Molecular designs, such as the incorporation of hydrophilic comonomers or graft copolymers in PNIPAAm hydrogels, enhance rapid kinetics of the gels when jumping the temperature across the phase transition temperature, because of avoiding 'skin layer' formation on the surface of the gels. Nanocarriers possessing PNIPAAm coronas facilitate spatial drug delivery and temporally on-demand drug release to targeted cancers in combination with hyperthermic therapy. Downsizing of PNIPAAm hydrogels accelerates the kinetics of shrinkage/swelling, leading to applications as thermoresponsive chromatographic matrices and cell cultureware. PNIPAAm-modified surfaces support thermoresponsive cell culture systems for the non-invasive recovery of intact cell sheets, enabling advanced regenerative therapies and layered 3D tissue formation. Recent developments also integrate growth factor delivery for sustained cell stimulation on culturewares. Newly developed biomaterials, including dynamically thermoresponsive PNIPAAm, are expected to expand the opportunity for novel treatment technologies such as targeted therapies and regenerative medicine.

01 Dec 2025·Cancer Chemotherapy and Pharmacology

Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment

Article

Author: Yamamoto, Koujirou ; Kogo, Mari ; Morita, Jun ; Sato, Miki Takenaka ; Fukagai, Takashi ; Araki, Takuya ; Yashima, Hideaki ; Maeda, Yoshiko ; Ohbayashi, Masayuki ; Kohyama, Noriko ; Ishikawa, Yuya ; Ogawa, Yoshio

PURPOSEThe blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment.METHODSThis study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson's correlation coefficient.RESULTSSeven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5-63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups.CONCLUSIONThis study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.

01 Aug 2025·International Journal of Cardiology

Long term prognosis in cardiac sarcoidosis under FDG-PET guided immunosuppressive therapy

Article

Author: Nagao, Michinobu ; Yamaguchi, Junichi ; Watanabe, Eri ; Imamura, Yasutaka ; Serizawa, Naoki ; Yamamoto, Atsushi ; Momose, Mitsuru ; Suzuki, Atsushi ; Uto, Kenta ; Sakai, Shuji

BACKGROUNDCardiac sarcoidosis (CS) is a granulomatous disease that can lead to heart failure and fatal arrhythmias. While ¹⁸F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is useful in assessing active inflammation, its role in guiding immunosuppressive therapy and predicting long-term prognosis remains unclear.METHODSThis retrospective study analyzed 36 CS patients who underwent FDG-PET-guided immunosuppressive therapy between 2012 and 2017. FDG uptake was quantitatively evaluated before treatment, at 6 and 12 months, and annually thereafter. Prognostic outcomes, including major adverse cardiac events (MACE) and mortality, were assessed.RESULTSOver a median follow-up of 8.2 years, 11 patients experienced MACE, and 7 died. SUVmax at 6 months (six-M SUVmax) and 1 year (one-y SUVmax) significantly correlated with prognosis. Patients with one-y SUVmax >4.5 had a higher risk of adverse events (p < 0.0001), while patients with six-M SUVmax >3.5 had a higher risk of adverse events (p = 0.035). Lower left ventricular ejection fraction (LVEF <40 %) was also associated with worse outcomes. Those requiring a final prednisolone (PSL) dose ≥10 mg had increased mortality (p < 0.0001).CONCLUSIONFDG-PET-derived SUVmax at 1 year is a critical prognostic indicator in CS patients undergoing immunosuppressive therapy. Poor response to PSL, indicated by persistent FDG uptake, correlates with worse outcomes. Regular FDG-PET monitoring and personalized treatment strategies are essential to optimizing long-term management.

100 Deals associated with Tokyo Women's Medical University

100 Translational Medicine associated with Tokyo Women's Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NIP-141 ( Potassium channel )	Atrial Fibrillation More	Pending
RNF43-721	Colorectal Cancer More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tokyo Women's Medical University

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 May 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing